perphenazine GABA ester: Clinical Trials

4 completed, 1 terminated. 4 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia CYP-1020, Risperidone - Schizophrenia, Cognitive Effect on Schizophrenic Patients	Phase 2 / Phase 3	Terminated	BioLineRx, Ltd.	269	2011-05-01	2014-09-18
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study BL - 1020, Placebo, Risperidone - Schizophrenia	Phase 2	Completed	BioLineRx, Ltd.	360	2008-07-01	2010-06-29
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 BL-1020, BL-1020 10-30 mg, risperidone - Schizophrenia	Phase 2	Completed	BioLineRx, Ltd.	220	2008-06-01	2010-06-29
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder BL-1020, BL 1020 High Dose - Schizophrenia, Schizoaffective Disorder	Phase 2	Completed	BioLineRx, Ltd.	90	2007-06-01	2009-07-21
A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer BL 1020, Perphenazine - Healthy	Phase 1	Completed	BioLineRx, Ltd.		2007-05-01	2009-07-21